1 ACR Guidelines 2000 American College of Rheumatology Subcommittee on osteoarthritis guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 Update. Arthritis & Rheumatism. 2000;43:1905-15.
2 Peyron JG, Balazs EA. Preliminary clinical assessment of Na-hyaluronate injection into human arthritic joints. Pathologie-Biologie (Paris). 1974;22:731-6.
3 Weiss C, Band P. Basic principles underlying the development of viscosupplementation for the treatment of osteoarthritis. Journal of Clinical Rheumatology. 1999;5:2-11.
4 Hou SM, Wang CT. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. The Journal of Bone and Joint Surgery. American Volume. 2004;86-A:2567.
5 Frizziero L, Pasquali Rochetti I. Intra-articular treatment of osteoarthritis of the knee: an arthroscopic and clinical comparison between sodium hyaluronate (500-730 kDa) and methylprednisolone acetate. Journal of Orthopaedics and Traumatology. 2002;3:89-96.
6 Leopold SS, Redd BB, Warme WJ, Wehrle PA, Pettis PD, Shott S. Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee. A prospective, randomized trial. The Journal of Bone and Joint Surgery. American Volume. 2003;85-A:1197-203.
7 Tsukamoto Y, Yamamoto M, Motegi M, Iwata H, Ryu J, Takagishi K, Sugawara S. A double-blind trial of intra-articular higher molecular weight hyaluronic acid (NRD 101) versus lower molecular weight hyaluronic acid (Artz®) in knee osteoarthritis. Rheumatology in Europe. 1995;24:333.
8 Yamamoto M, Sugawara Y, Tsukamoto Y, Motegi M, Iwata H, Rye J, Takagishi K, Nakashima M. Clinical evaluation of high molecular weight sodium hyaluronate (NRD 101) on osteoarthritis of the knee. A phase III comparative clinical study with Artz as a control drug. Japanese Pharmacology & Therapeutics. 1994;22:4059-87.
9 Karatosun V, Unver B, Gocen Z, Sen A, Gunal I. Intra-articular hyaluronic acid compared with progressive knee exercises in osteoarthritis of the knee: a prospective randomized trial with long-term follow-up. Rheumatology International. 2006;26:277-84.
10 Huang MH, Yang RC, Lee CL, Chen TW, Wang MC. Preliminary results of integrated therapy for patients with knee osteoarthritis. Arthritis and Rhemuatism. 2005;53:812-20.
11 Rejaili WA, Chueire AG, Cordeiro JA, Petean FC, De Carvalho Filho G. The evaluation of hilan GF-20 in the postoperative knee arthroscopies for arthrosis. Acta Ortopédica Brasileira. 2005;13:20-3.
12 Forster MC, Straw R. A prospective randomised trial comparing intra-articular Hyalgan injection and arthroscopic washout for knee osteoarthritis. The Knee. 2003;10:291-3.
13Ahlbäck S, Bauer GC, Bohne WH. Spontaneous osteonecrosis of the knee. Arthritis and Rheumatism. 1968;11:705-33.
14 Chan D, Cole WG, Chow CW, Mundlos S, Bateman JF. A COL2A1 mutation in achondrogenesis type II results in the replacement of type II collagen by type I and III collagens in cartilage. Journal of Biological Chemistry. 1995;270:1747-53.
15 Meulenbelt I, Bijkerk C, De Wildt SC, Miedema HS, Breedveld FC, Pols HA, Hofman A, Van Duijn CM, Slagboom PE. Haplotype analysis of three polymorphisms of the COL2A1 gene and associations with generalised radiological osteoarthritis. Annals of Human Genetics. 1999:393-400.
16 Hannan MT, Anderson JJ, Zhang Y, Levy D, Felson DT. Bone mineral density and knee osteoarthritis in elderly men and women. Arthritis and Rheumatism. 1993;36:1671-80.
17 Zhang Y, Hannan MT, Chaisson CE, McAlindon TE, Evans SR, Aliabadi P, Levy D, Felson DT. Bone mineral density and risk of incident and progressive radiographic knee osteoarthritis in women: the Framingham Study. The Journal of Rheumatology. 2000;27:1032-7.
18 Hart D, Mootoosamy I, Doyle D, Spector T. The relationship between osteoarthritis and osteoporosis in the general population: the Chingford Study. Annals of the Rheumatic Diseases. 1994;53:158-62.
19 Eli Steigelfest, Carlos J Lozada. Osteoarthritis. eMedicine. January 22, 2002.
20 Zhang Y, Xu L, Nevitt MC, Aliabadi P, Yu W, Qin M, Lui LY, Felson DT. Comparison of the prevalence of knee osteoarthritis between the elderly Chinese population in Beijing and Whites in the United States. The Beijing Osteoarthritis Study. The Journal of Rheumatology. 2001;44:2065-71.
21蔡怡萱、周正亮. 常見膝與手的退化性關節炎. 臨床醫學. 民國95年12月 第58卷第6期:423-7.22 Rydell N, Balazs EA. Effect of intraarticular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. Clinical Orthopaedics and Related Research. 1971;80:25-32.
23 Hsieh YS, Yang SF, Chu SC, Chen PN, Chou MC, Hsu MC, Lu KH. Expression changes of gelatinases in human osteoarthritic knees and arthroscopic debridement. Arthroscopy. 2004;20:482-8.
24 Murphy G, Knauper V, Atkinson S, Butler G, English W, Hutton M, Stracke J, Clark I. Matrix metalloproteinases in arthritic disease. Arthritis Research. 2002;4:39-49.
25 Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. The EMBO Journal. 1997;16:2319-32.
26 Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors:hormonally regulated serpins. Molecular and Cellular Endocrinology. 1990;68:1-19.
27 Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. Journal of Biological Chemistry. 1999;274:13066-76.
28 Matsuo O, Tanaka S, Kikuchi H. Effect of urinary trypsin inhibitor on osteoarthritis. Thrombosis Research. 1988;52:237-245.
29 Ghosh P, Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Seminars in Arthritis and Rheumatism. 2002;32:10-37.
30 Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of the WOMAC: A health status instrument for measuring clinically-important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. The Journal of Rheumatology. 1988;15:1833-40.
31 Founded in 1863, the Hospital for Special Surgery is a world leader in orthopedics, rheumatology and rehabilitation. Ranked No. 1 in the Northeast in its specialties by U.S. News and World Report''s, HSS score was awarded Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center. A member of the New York-Presbyterian Healthcare System and an affiliate of Weill Medical College of Cornell University, HSS score provides orthopedic and rheumatologic patient care at New York-Presbyterian Hospital at New York Weill Cornell Medical Center. All HSS score medical staff members are on the faculty of Weill Medical College of Cornell University. Its Research Institute is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. The hospital is located in New York City, www.hss.edu
32 Lequesne M, Brandt KD, Bellamy N. Guidelines for testing slow-acting and disease-modifying drugs in osteoarthritis. The Journal of Rheumatology. 1994;21:65-71.
33 Takahashi K, Goomer RS, Harwood F, Kubo T, Hirasawa Y, Amiel D. The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-1beta (IL-1beta), and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthritis and Cartilage /OARS, Osteoarthritis Research Society. 1999;7:182-90.
34 Nonaka T, Kikuchi H, Ikeda T, Okamoto Y, Hamanishi C, Tanaka S. Hyaluronic acid inhibits the expression of u-PA, PAI-1, and u-PAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis. The Journal of Rheumatology. 2000;27:997-1004.
35 Takahashi K, Hashimoto S, Kubo T, Hirasawa Y, Lotz M, Amiel D. Hyaluronan suppressed nitric oxide production in the meniscus and synovium of rabbit osteoarthritis model. Journal of Orthopaedic Research. 2001;19:500-3.
36 Aviad AD, Houpt JB. The molecular weight of therapeutic hyaluronan (sodium hyaluronate): how significant is it?. The Journal of Rheumatology. 1994;21:297-301.
37 Lo GH, La Valley M, McAlindon T, Felson DT. Intra-articular hyaluronic acid in treatment of knee osteoarthritis. A meta-analysis. The Journal of the American Medical Association. 2003;290:3115-21.
38 Maneiro E, de Andres MC, Fernandez-Sueiro JL, Galdo F, Blanco FJ. The biological action of hyaluronan on human osteoarthritic articular chondrocytes: the importance of molecular weight. Clinical and Experimental Rheumatology. 2004;22:307-12.
39 Espallargues M, Pons JMV Efficacy and safety of viscosupplementation with Hylan G-F 20 for the treatment of knee osteoarthritis. A systematic review. International Journal of Technology Assessment in Health Care. 2003;19:41-56.
40 Berstein J. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. The Journal of Bone and Joint Surgery. American Volume. 2004;86-A:2567.
41 Modawal A, Ferrer M, Choi HK, Castle JA. Hyaluronic acid injections relieve knee pain. The Journal of Family Practice. 2005;54:758-67.
42 Day R, Brooks P, Conaghan PG, Petersen M; Multicenter Trial Group. A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the knee. The Journal of Rheumatology. 2004;31:775-82.
43 Puhl W, Bernau A, Greiling H, Kopcke W, Pforringer W, Steck KJ, Zacher J, Scharf HP. Intra-articular sodium hyaluronate in osteoarthritis of the knee: a multicenter, double-blind study. Osteoarthritis and Cartilage /OARS, Osteoarthritis Research Society. 1993;1:233-41.
44 Shichikawa K. Evaluation of the effect of sodium hyaluronate (SPH) to osteoarthritis of the knee. The Ryumachi. 1983;23:280-90.
45 Shichikawa K, Igarashi M, Sugawara S, Iwasaki Y. Clinical evaluation of high molecular weight sodium hyaluronate (SPH) on osteoarthritis of the knee - a mutli-center well controlled comparative study. Japanese Journal of Clinical Pharmacology and Therapeutics. 1983;14:545-58.
46 Wu JJ, Shih LY, Hsu HC, Chen TH. The double-blind test of sodium hyaluronate (Artz®) on osteoarthritis knee. Chinese Medical Journal (Taipei). 1997;59:99-106.
47 Lohmander LS, Dalen N, Englund G, Hamalainen M, Jensen EM, Karlsson K, Odensten M, Ryd L, Sernbo I, Suomalainen O, Tegnander A, The Hyaluronan Multicentre Trial Group. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Annals of the Rheumatic Diseases. 1996;55:424-31.
48 Karlsson J, Sjogren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology. 2002;41:1240-8.
49 Adams ME, Atkinson MH, Lussier AJ, Schulz JI, Siminovitch KA, Wade JP, Zummer M. The role of viscosupplementation with hylan G-F 20 (Synvisc®) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis and Cartilage /OARS, Osteoarthritis Research Society. 1995;3:213-6.
50 Wobig M, Bach G, Beks P, Dickhut A, Runzheimer J, Schwieger G, Vetter G, Balazs E. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clinical Therapeutics. 1999;21:1549-62.
51 Brown DJ, Beinat L. Safety and efficacy of an hyaluronan of 500-730 KDa and Hylan G-F 20 in clinical practice. Osteoarthritis and Cartilage /OARS, Osteoarthritis Research Society. 2003;11:118.
52 Caborn D, Rush J, Lanzer W, Parenti D, Murray C on Behalf of the Synvisc® 901 Study Group. A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. The Journal of Rheumatology. 2004;31:333-43.
53 Cubukcu D, Ardic F, Karabulut N, Topuz O. Hylan G-F 20 efficacy on articular cartilage quality in patients with knee osteoarthritis: clinical and MRI assessment. Clinical Rheumatology. 2005;24:336-41.
54 Dickson DJ, Hosie G, English JR, and the Primary Care Rheumatology Society. A double-blind, placebo-controlled comparison of hylan G-F 20 against diclofenac in knee osteoarthritis. Journal of Clinical Research. 2001;4:41-52.
55 Scale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Current Therapeutic Research. 1994;55:220-32.